Compare AMPL & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPL | ABSI |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 997.8M |
| IPO Year | 2021 | 2021 |
| Metric | AMPL | ABSI |
|---|---|---|
| Price | $10.71 | $8.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $13.42 | $6.96 |
| AVG Volume (30 Days) | 1.9M | ★ 3.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.84 | 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $343,214,000.00 | $4,534,000.00 |
| Revenue This Year | $17.43 | $215.96 |
| Revenue Next Year | $14.16 | $319.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.68 | N/A |
| 52 Week Low | $5.51 | $2.24 |
| 52 Week High | $12.80 | $12.06 |
| Indicator | AMPL | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.